Literature DB >> 34285111

Comparison of area under the curve for vancomycin from one- and two-compartment models using sparse data.

Nyein Hsu Maung1, Janthima Methaneethorn2, Thitima Wattanavijitkul1, Tatta Sriboonruang3.   

Abstract

BACKGROUND AND
OBJECTIVE: Vancomycin pharmacokinetics have been described by both one- and two-compartment models. One-compartment models are widely used to predict the area under the curve (AUC), a useful parameter for determining the efficacy and safety of vancomycin, based on sparse data collected during therapeutic drug monitoring. It is uncertain whether AUCs from one-compartment models with sparsely sampled data can sufficiently represent the true AUC. This study aimed to compare AUC estimates from one- and two-compartment models using sparse data. The reliability of AUCs from models constructed with trough-only data was also assessed.
METHODS: A previously published robust model was used to simulate vancomycin concentration points at 15 min intervals in 100 patients. From these simulated data, the reference AUC (AUCref) was calculated and two depleted dataset versions (trough-only and peak-trough datasets) were also created. One- and two-compartment models were built from the depleted datasets with the use of NONMEM. Vancomycin 24-hour AUC was calculated from concentration-time profiles of each model by a linear trapezoidal formula at three different time periods: 0-24 hours (AUC0-24), 24-48 hours (AUC24-48) and 0-48 hours (AUCavg). The deviation of each of the AUCs from the AUCref was examined to assess the AUC predictability of models from sparse data. The difference in AUCs between one- and two-compartment models was analysed from statistical and clinical perspectives.
RESULTS: When assessing the deviation of each AUC from the AUCref, the one-compartment model from both peak-trough and trough-only data could adequately represent the true AUC with no statistically significant differences. Two-compartment model from peak-trough data also provided similar AUC estimates with the AUCref. However, AUCs from the two-compartment model with trough-only data did not adequately represent the true AUC, with significant differences of 25.16% for AUC0-24, 15.92% for AUC24-48 and 19.45% for AUCavg.
CONCLUSION: Regardless of statistically significant differences between AUCs from one- and two-compartment models, the level of difference was acceptable from the clinical perspective, being <17% in models from peak-trough data. Therefore, both one- and two-compartment models with sparse data having at least a pair of peak-trough data per patient could be reliable for predicting AUC. Furthermore, AUCs of the one-compartment model from trough-only data did not show a significant difference from the AUCref. Hence, one-compartment models developed from trough-only data could be useful for predicting AUC when models with rich data are not available for the intended population. However, it is suggested that the use of the two-compartment model built from trough-only data should be avoided. © European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  clinical medicine; drug monitoring; education; hospital; microbiology; pharmacy; pharmacy service

Mesh:

Substances:

Year:  2021        PMID: 34285111      PMCID: PMC8899690          DOI: 10.1136/ejhpharm-2020-002637

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  44 in total

Review 1.  The pharmacokinetic and pharmacodynamic properties of vancomycin.

Authors:  Michael J Rybak
Journal:  Clin Infect Dis       Date:  2006-01-01       Impact factor: 9.079

2.  Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?

Authors:  A J Heffernan; A Germano; F B Sime; Jason A Roberts; E Kimura
Journal:  Eur J Clin Pharmacol       Date:  2019-06-01       Impact factor: 2.953

3.  Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes.

Authors:  Dinh H Vu; Duy A Nguyen; Isabelle K Delattre; Trong T Ho; Hong G Do; Hong N Pham; Xuan C Dao; Nhan T Tran; Gia B Nguyen; Françoise Van Bambeke; Paul M Tulkens; Hoang A Nguyen
Journal:  Int J Antimicrob Agents       Date:  2019-10-07       Impact factor: 5.283

4.  Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.

Authors:  Natalia Revilla; Ana Martín-Suárez; Marta Paz Pérez; Félix Martín González; María Del Mar Fernández de Gatta
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

5.  Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens.

Authors:  Jason A Roberts; Fabio Silvio Taccone; Andrew A Udy; Jean-Louis Vincent; Frédérique Jacobs; Jeffrey Lipman
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

6.  Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.

Authors:  Eyob D Adane; Michael Herald; Firas Koura
Journal:  Pharmacotherapy       Date:  2015-02-03       Impact factor: 4.705

7.  Population Pharmacokinetics of Vancomycin in Postoperative Neurosurgical Patients.

Authors:  Xingang Li; Yuanxing Wu; Shusen Sun; Shenghui Mei; Jiaqing Wang; Qiang Wang; Zhigang Zhao
Journal:  J Pharm Sci       Date:  2015-08-03       Impact factor: 3.534

8.  Pharmacokinetics of vancomycin and dosing recommendations for trauma patients.

Authors:  Susanna E Medellín-Garibay; Belén Ortiz-Martín; Aída Rueda-Naharro; Benito García; Silvia Romano-Moreno; Emilia Barcia
Journal:  J Antimicrob Chemother       Date:  2015-11-14       Impact factor: 5.790

9.  Development and comparison of population pharmacokinetic models of vancomycin in neurosurgical patients based on two different renal function markers.

Authors:  Li Jing; Tao-Tao Liu; Qing Guo; Ming Chen; Jie-Jiu Lu; Chun-le Lv
Journal:  J Clin Pharm Ther       Date:  2019-08-28       Impact factor: 2.512

10.  A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Therapy.

Authors:  J N Moore; J R Healy; B N Thoma; M M Peahota; M Ahamadi; L Schmidt; N C Cavarocchi; W K Kraft
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.